Turkey country overview

Turkey country overview

Map of Turkey

About NFP: 

The Turkish Monitoring Centre for Drugs and Drug Addiction (TUBİM) is attached to the Ministry of Interior/Turkish National Police/Counter Narcotics Department. It is responsible for the coordination and implementation of the national drug strategy on behalf of the Ministry of Interior and for monitoring the drug situation of the whole country. It does this through its network of Provincial Focal Points around the country. TUBİM also manages Turkey’s National Early Warning System for monitoring new psychoactive substances. Comprised of academics from a range of disciplines, TUBİM’s Scientific Committee reviews evidence related to drug policy issues and provides advice to government.

E-mail addresses have been inserted in a way discouraging spam. Please replace [a] by @ before actually using any of the e-mail addresses.

Last updated: Friday, May 27, 2016

Drug use among the general population and young people

Content for prevalence: 

The first general population study on the prevalence of drug use in Turkey was conducted in 2011 by the Turkish Monitoring Centre for Drugs and Drug Addiction (TUBİM). The study covered 25 regions (the Van region was not included, as an earthquake occurred there during the study period) with a sample of 8 045 people aged 15–64, and the response rate was 43.9 %. The European Model Questionnaire was adapted to the national context and face-to-face interviews were carried out with the respondents. Around 2.7 % indicated use of any illicit substance during their lifetime, and cannabis was the most prevalent illicit substance ever used, at 0.7 % of the respondents. About 0.3 % of respondents had used cannabis in the last 12 months, while 0.2 % had used it in the last 30 days. Lifetime prevalence rates for amphetamines were reported at 0.3 %, followed by ecstasy at 0.1 %. The highest rates of illicit drug use were reported among males aged 15–34. Thus 1.6 % of male respondents in this age group had ever used cannabis, 0.7 % had used amphetamine and 0.2 % had used ecstasy. The study indicated that among females drug use prevalence increased between the ages of 25–44, and twice as many female respondents reported using tranquilisers or sedatives without a doctor’s prescription.

In 2003 the European School Survey Project on Alcohol and Other Drugs (ESPAD) with a sample size of 6 149 young people aged 15–16 was conducted in six metropolitan cities (Adana, Ankara, Diyarbakır, İstanbul, İzmir and Samsun). The study found a lifetime prevalence of 5 % for inhalants, 4 % for cannabis, 2 % for ecstasy, 2 % for heroin and 2 % for cocaine. Last year prevalence for cannabis use was reported by 5 % of the students, and last month prevalence by 3 %.

In 2011 TUBİM conducted an attitude and behaviour survey on tobacco, alcohol and drug use among students in the second year of high school (age range: 14–19), using a self-administered questionnaire. About 1.0 % of 15-year-old students reported lifetime use of any drug, while the proportion increased to 1.5 % if all respondents were considered. About 0.3 % of all respondents reported ever having used cannabis, although this rate should be treated with caution as it was calculated based on open-ended questions to which responses were frequently not given.

Look for Prevalence of drug use in the Statistical bulletin for more information.


Content for prevention: 

The new Action Plan, adopted in 2015, tasks the Ministry of National Education to coordinate all prevention activities in the country. Moreover, the Ministry of Family and Social Policies, Ministry of Health and Turkish Green Crescent society are mentioned as the main implementing agencies for prevention activities. From 2015 TUBİM Provincial Contact Points were no longer involved in prevention activities at the provincial level.

In addition to its overall coordinating role, the Ministry of National Education is directly responsible for the implementation of universal drug prevention in Turkish schools. At the local level, provincial steering committees chaired by deputy governors have been established to prepare action plans in line with the needs of their provinces.

The main prevention programmes undertaken in Turkey focus on increasing people’s awareness of drugs and the dissemination of information. Some initiatives have recently been launched that aim to increase individual and social skills among young people and to support environments that may deter drug-taking among vulnerable populations.

Prevention interventions are mostly targeted at young people, and many of them are implemented in the educational system, but some activities are also supported by non-governmental organisations. The methods used include counselling support, seminars, discussion panels and conferences. Manualised programmes are rare. Various conferences, seminars, theatre performances and awareness-raising activities have been organised mainly by the Ministry of Interior–Turkish National Police (TUBİM) in the last five years, around the themes of alcohol and drug addiction. There are some family-oriented prevention projects carried out in cooperation with school counselling centres. At the community level, prevention activities are mainly informative; until 2015 they were organised by TUBİM Provincial Contact Points, Provincial Directorates of Public Health and the Department of Religious Affairs. The few selective prevention interventions that are available generally focus on awareness-raising and information provision, while Social Services Centres provide some social assistance and referrals to treatment institutions for homeless children and young people. Indicated prevention has not yet been developed in Turkey.

No research studies have yet been undertaken on the effectiveness and outcomes of prevention interventions.

See the Prevention profile for Turkey for more information.

Problem drug use

Content for problem drug use: 

Up to 2012 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defined problem drug use as injecting drug use or long duration/regular use of opiates, cocaine and/or amphetamines. However, in 2012 a new definition of ‘high-risk drug use’ was adopted. The new definition includes ‘problem drug use’, but is broader (mainly in its inclusion of high-risk use of more substances). Details are available here.

A population size estimate of high-risk opioid users has been performed in Turkey for all years between 2007 and 2011, using the mortality multiplier method. The most recent study, from 2011, suggested that there were around 12 733 opioid users (sensitivity interval: 11 126–26 537), which corresponds to a rate of 0.3 opioid users per 1 000 population aged 15–64 (sensitivity interval: 2.1–3.9).

Look for High-risk drug use in the Statistical bulletin for more information.

Treatment demand

Content for treatment demand: 

Treatment demand data in Turkey are provided by the Directorate-General for Health Services of the Ministry of Health through a drug treatment notification form. In 2014 data were reported from all 32 operational inpatient treatment centres.

In 2014 a total of 10 630 clients entered inpatient treatment, of which 5 600 were new clients entering treatment for the first time. Some 70 % of all treatment clients reported opioids as their primary drug, followed by 9 % for cannabis and 2 % for volatile inhalants. A similar pattern was identified among new treatment clients, with 61 % reporting opioids, mainly heroin, followed by 11 % for cannabis and 2 % for volatile inhalants. It is notable that about 16 % of all treatment entries were linked to other substances, among which the vast majority were synthetic cannabinoids. Injecting drug use was reported by 30 % of all treatment clients and 20 % of new treatment clients who demanded treatment due to the use of opioids. From 2006 to 2014 the number of clients entering treatment for opioid use, and heroin in particular, has increased fivefold, primarily due to the increased availability of treatment for opioid addiction in Turkey.

The mean age of all treatment clients was 26, while the average age of new treatment clients was 25. The gender distribution was similar among all and new treatment clients, with 95 % and 96 % male clients respectively.

Look for Treatment demand indicator in the Statistical bulletin for more information.

Drug-related infectious diseases

Content for drug-related infectious diseases: 

The Public Health Agency of the Ministry of Health and the Directorate-General for Health Services of the Ministry of Health provides data on human immunodeficiency virus (HIV) in Turkey. In 2014 the Public Health Agency recorded 10 new HIV cases among people who inject drugs (PWID).

Hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV testing is also carried out among PWID admitted to the Alcohol-Substance Addiction Research, Therapy and Education Centres (AMATEM). In 2014 some 0.2 % of 3 090 clients tested were HIV positive, 4.2 % were HBV positive and 42.8 % were HCV positive.

In 2012 around 912 HCV and 156 HBV cases with injecting drug use as a likely transmission route were reported in Turkey. Since the transmission routes were not provided by the patients, the transmission routes for all the HCV and HBV cases are assumed to be due to injecting drug use.

Look for Drug-related infectious diseases in the Statistical bulletin for more information.

Drug-induced deaths and mortality

Content for drug-induced deaths: 

Drug-induced deaths are reported by the Council of Forensic Medicine under the Ministry of Justice from a special death registry, which is based on autopsy reports from across Turkey. Data extraction and reporting is in line with EMCDDA definitions and recommendations.

In 2014 some 497 drug-induced deaths were reported, which is twice as many as in 2013 and the highest number reported during the observation period. The overall trend indicated a steady increase in reported drug-induced deaths from 2007 to 2009, with a slight decrease in 2010, while in 2011 the increasing trend resumed. In 2014 the majority of the deceased were male (467). The mean age of victims was 30.4 years. Toxicological analysis was available for all confirmed drug-induced deaths, and opiates were involved in 287 reported death cases. However, more than one substance was detected in over two-thirds of the deaths. In one in five cases synthetic cannabinoids were present, while in 40 cases they were identified as a cause of deaths. It is hypothesised that fluctuations in the number of drug-induced deaths in Turkey may be linked to changes in the heroin supply as a result of fluctuations in opium production activities in Afghanistan, where a decline was observed in 2010 and a subsequent increase in 2012. The high purity of illicit substances, heroin in particular and also ecstasy, together with an increase in stimulant and poly-substance use, are also mentioned as likely reasons for to the most recent increase in reported drug-induced deaths. Part of the increase might be due to improved detection and reporting capacity in Turkey.

The drug-induced mortality rate among adults (aged 15–64) was 9.2 deaths per million in 2014, lower than the most recent European average of 19.2 deaths per million.

Look for Drug-related deaths in the Statistical bulletin for more information.

Treatment responses

Content for treatment responses: 

The implementation of drug-related treatment in Turkey falls under the responsibility of the Ministry of Health, and the Science Committee for Substance Addiction is responsible for its national coordination, while since the end of 2013 Provincial Healthcare Directorates have been authorised to license and supervise substance abuse treatment centres.

Treatment is provided through the Alcohol-Substance Addiction Research, Therapy and Education Centres (AMATEMs), psychiatric clinics of public hospitals under the Ministry of Health, and university-based treatment units. In 2015 there were 36 treatment centres in Turkey, of which 33 also provided inpatient services. The majority of drug-related treatment services take place in inpatient settings. Funding for drug-treatment services is mainly provided by the state through social or health insurance funds.

The majority of treatment services for drug users treat addiction in general, providing treatment for both alcohol and illicit drugs. The primary approach of treatment programmes is to help clients achieving a drug-free state. An essential part of the treatment is detoxification, usually in the inpatient setting, which is complemented with other interventions consisting of motivational interviewing techniques and cognitive therapies that aim to prevent relapse.

In 2009 a combined buprenorphine/naloxone medication was licensed in Turkey, and it has been used in drug addiction treatment for detoxification and substitution since 2010. Opioid substitution treatment (OST) was initially prescribed by psychiatrists within AMATEMs, but since 2014 all addiction centres licensed by the Ministry of Health have been able to implement OST. Up to 80 % of OST medication costs are covered by the General Health Insurance, while client contribute 20 % of the costs. The latest available data from 2012 indicate that about 28 656 clients in Turkey receive OST with a buprenorphine-based medication.

See the Treatment profile for Turkey for additional information.

Harm reduction responses

Content for harm reduction responses: 

Needle and syringe exchange programmes are not available in Turkey.

See the Harm reduction overview for Turkey for additional information.

Drug markets and drug-law offences

Content for Drug markets and drug-law offences: 

Heroin originating from Afghanistan is trafficked through Turkey to central and western Europe via the Balkan route. Cannabis is mainly produced for the domestic market, and is subject to local and regional trafficking mostly carried out by family-type structures of 3–15 people. In addition to domestic cultivation, small amounts of cannabis are smuggled to Turkey from Iran and Syria. Cocaine enters Turkey from South America for domestic use and en route to other European countries, Azerbaijan and northern Iraq. Captagon (1) tablets originating in south-eastern Europe are smuggled through Turkey for domestic use and en route to countries in the Middle East, although there are indications that in recent years production of that substance has moved to the Middle East and its availability in the market has significantly declined. Methamphetamine, originating in Iran, was seized for the first time in 2009, and seizures of the substance have since increased. Methamphetamine seized in Turkey is primarily destined for the south-east Asia region and to a lesser extent for Europe and Syria, while the most recent data indicates the emergence of some alternative smuggling routes and methods for the substance. Ecstasy seized in Turkey originates in the Netherlands and Belgium, and is trafficked to Turkey mainly for the domestic market, primarily the larger urban and tourist areas along the Mediterranean and Aegean coastline. Synthetic cannabinoids, which emerged in the Turkish drug market in 2010, mainly originate in European countries, the United States of America and China.

In 2014 some 77 664 drug-law offences were registered in Turkey, which is less than in 2012 and 2013. Most of these offences were related to drug use or possession (78 %). A substantial proportion of offences (63 %) were related to cannabis, 9 % to heroin and 5 % to ecstasy.

In 2014 the number of illicit drug seizures and amounts of drugs seized were lower than in 2013 for all main illicit drugs monitored and reported. Cannabis products remain the most frequently seized drugs, and data available since 2003 show an increase in the seized quantities of herbal cannabis and cannabis resin. In 2014, however, both substances were seized less frequently and the amounts seized almost halved when compared to 2013. In 2014 a total of 92 480.87 kg of herbal cannabis was seized in 41 594 law enforcement activities, while 3 972 law enforcement activities resulted in 30 634.74 kg of cannabis resin seized. In 2014 a total of 3 017 seizures of cannabis plants were reported, which is less than reported annually in 2009–13.

The quantity of heroin seized sharply increased from 3 710 kg in 2001 to 16 059 kg in 2009, while in the following years the amount seized fell to 7 294 kg in 2011, indicating a heroin shortage in the market. In 2012, however, the amount seized increased to 13 301 kg, and remained at the same level in the following years. In 2014 a total of 12 755.54 kg of heroin was seized.

Cocaine seizures increased approximately fourfold in the period 2008–12 (from 94 kg to 476 kg). In 2011 a record quantity of 592 kg was seized, which is explained by the seizure of a large amount of the substance in one large operation. In 2013 and 2014 a total of 450 kg and 393.203 kg of cocaine was seized respectively.

Although there was a rapid decline in Captagon seizures after 2008, in 2013 a new record amount of more than 4.5 million Captagon tablets were seized, almost all in a single operation that seized tablets en route from Syria to the Arabian Peninsula. In 2014 a total of 239 Captagon seizures were reported, with 652 027 pills seized.

Following a record number of 4.5 million tablets of ecstasy seized in 2013, in 2014 a total of 3.6 million were seized. The number of methamphetamine seizures continued to increase until 2012, following the first seizures in 2009, but in 2013 a total quantity of 105.176 kg of the substance was seized, less than in 2012 when 502 kg was seized. In 2014 synthetic cannabinoids were the second most frequently seized substance in Turkey, following herbal cannabis. In 2014 a total amount of 734 kg of synthetic cannabinoid products were seized (slightly less than in 2013, when 780 kg were seized).

(1) Pills that have a captagon label, look like captagon and have amphetamines as their active substances.

Look for Drug-law offences in the Statistical bulletin for additional data.

National drug laws

Content for National drug laws: 

The Turkish Penal Code, updated in 2014, sets prison sentences of two to five years for those who use drugs or buy, receive or possess drugs for personal use. There is also the option of treatment and/or probation of up to three years, but since 2014 probation as an alternative to prison cannot be given more than once. If addicts refuse treatment or do not comply with probation requirements, the courts can decide on sentencing.

The production and import or export of drugs are punished by a sentence of 20–30 years, and sale or supply by a sentence of not less than 10 years, or 15 years if supplied to a minor. In this case, punishments are linked to drug type, with a specific requirement to increase these sentences by 50 % if the drugs involved are cocaine, heroin, morphine or morphine base, or synthetic cannabinoids; a similar increase is imposed in cases where a group of people is involved, or where those convicted held positions linked to legal trades, such as doctors, pharmacists, health officers, etc. If organised crime is involved, the penalty is doubled.

Go to the European Legal Database on Drugs (ELDD) for additional information.

National drug strategy

Content for National drug strategy: 

Turkey’s drug policy is expressed in its 2015 National Anti-Drug Strategy Paper. The Strategy is built around the pillars of drug demand and drug supply reduction and addresses key issues across 12 thematic areas. These are: preventing access to drugs; taking measures in relation to educational institutions; identifying target groups; anti-drug counselling units; strengthening drug dependence treatment. social reintegration; scientific advisory board for anti-drug activities; anti-drug decision support system; legislation for anti-drug activities; coordination and cooperation; communication with the public; diagnosis and laboratory services. The strategy is a long-term document with an open-ended timeframe. It is supported by the 2015 National Anti-Drug Action Plan. The Action Plan sets out a range of measures to implement the objectives of the 12 thematic areas of the National Anti-Drug Strategy Paper.

Coordination mechanism in the field of drugs

Content for Coordination mechanism in the field of drugs: 

The High Council for the Fight Against Drugs is responsible for inter-ministerial coordination on drug policies issues in Turkey. It is tasked with high-level strategy development, inter-institutional coordination, and monitoring of strategy implementation. The High Council includes ministers from all relevant ministries involved in delivering the national drug strategy.

The Board for the Fight Against Drugs supports the work of the High Council. It is responsible for executive operational day-to-day coordination and oversees the implementation and monitoring of the national drug strategy. The Technical Board for the Fight Against Drugs is an advisory body that assists the Board in its work and includes a range of specialised members.

The Turkish Monitoring Centre for Drugs and Drug Addiction (TUBİM) is attached to the Ministry of Interior/Turkish National Police/Counter Narcotics Department. It is responsible for the coordination and implementation of the national drug strategy on behalf of the Ministry of Interior and for monitoring the drug situation of the whole country. It does this through its network of Provincial Focal Points around the country. TUBİM also manages Turkey’s National Early Warning System for monitoring new psychoactive substances. Comprised of academics from a range of disciplines, TUBİM’s Scientific Committee reviews evidence related to drug policy issues and provides advice to government.

There are currently 81 Provincial and District Boards for the Fight Against Drugs throughout Turkey, covering all provinces. Provincial drug action plans have been established in 81 provinces. The tasks of the Secretariat for the provincial action plans and the Provincial Coordination Committees are carried out by a governorship in one province, and coordinated by the Provincial Health Directorates in all provinces.

Public expenditure

Content for Public expenditure: 

In Turkey, the financing of drug-related activities is decided annually by the entities in charge of their implementation.

Until 2011 the reporting of drug-related public expenditures was very limited and incomplete. In 2011 a preliminary questionnaire was sent to drug-related public services for the first time and this has been improved every year since 2012. Estimates suggest that drug-related public expenditure was TRY 743 546 907 in 2013 (0.05 % of gross domestic product (GDP)), partly boosted by an extraordinary investment in equipment and infrastructures. In 2014 this expenditure fell to TRY 529 858 200, which represented 0.07 % of GDP. However, the completeness of this estimate is unknown.

Drug-related research

Content for Drug-related research: 

To date, research has mainly been carried out by professionals in treatment centres. Recently, however, there has been an increasing interest in the field of drug-related research, with the support of the EMCDDA, through the national focal point. There is no specific budget for public institutions to carry out drug research, but funds are available for some studies. A number of non-government organisations carry out drug research. In recent years the national focal point, through support provided by a number of European Union projects, has been promoting research in this field amongst partners and universities. Some studies have already been put in place, including problem drug use estimation in three cities, a pilot general population survey, a student population survey and an infectious diseases survey. Publication in this field is limited. The Turkey Drug Conference takes place annually.

Recent drug-related studies mainly focus on aspects related to the prevalence, incidence and patterns of drug use.

See Drug-related research for more detailed information.

Data sheet — key statistics on the drug situation

Content for Data sheet: 

        EU range      
  Year   Country data Min. Max.      
Problem opioid use (rate/1 000) 2011   0.26 0.2 10.7      
All clients entering treatment (%) 2014   70.3% 4% 90%      
New clients entering treatment (%) 2014   61.1% 2% 89%      
Purity — heroin brown (%) 2014   32.9% 7% 52%      
Price per gram — heroin brown (EUR) 2010   EUR 23 EUR 23 EUR 140      
Prevalence of drug use — schools (%) :   : 1% 5%      
Prevalence of drug use — young adults (%) :   : 0% 4%      
Prevalence of drug use — all adults (%) :   : 0% 2%      
All clients entering treatment (%) 2014   1.3% 0% 38%      
New clients entering treatment (%) 2014   1.2% 0% 40%      
Purity (%) 2014   56.8% 20% 64%      
Price per gram (EUR) 2010   EUR 59 EUR 47 EUR 107      
Prevalence of drug use — schools (%) :   : 1% 7%      
Prevalence of drug use — young adults (%) 2011   0.1% 0% 3%      
Prevalence of drug use — all adults (%) :   : 0% 1%      
All clients entering treatment (%) 2014   0.3% 0% 70%      
New clients entering treatment (%) 2014   0.4% 0% 75%      
Purity (%) 2014   10.3% 1% 49%      
Price per gram (EUR) 2006   EUR 3 EUR 3 EUR 63      
Prevalence of drug use — schools (%) :   : 1% 4%      
Prevalence of drug use — young adults (%) 2011   0.1% 0% 6%      
Prevalence of drug use — all adults (%) :   : 0% 2%      
All clients entering treatment (%) 2014   1.0% 0% 2%      
New clients entering treatment (%) 2014   1.3% 0% 2%      
Purity (mg of MDMA base per unit) 2014   95 mg 27 mg 131 mg      
Price per tablet (EUR) 2010   EUR 7 EUR 4 EUR 16      
Prevalence of drug use — schools (%) :   : 5% 42%      
Prevalence of drug use — young adults (%) 2011   0.4% 0% 24%      
Prevalence of drug use — all adults (%) 2011   0.3% 0% 11%      
All clients entering treatment (%) 2014   9.0% 3% 63%      
New clients entering treatment (%) 2014   11.3% 7% 77%      
Potency — herbal (%) 2014   3.8% 3% 15%      
Potency — resin (%) 2013   2.9% 3% 29%      
Price per gram — herbal (EUR) 2010   EUR 5 EUR 3 EUR 23      
Price per gram — resin (EUR) 2010   EUR 9 EUR 3 EUR 22      
Prevalence of problem drug use                
Problem drug use (rate/1 000) :   : 2.7 10.0      
Injecting drug use (rate/1 000) :   : 0.2 9.2      
Drug-related infectious diseases/deaths                
HIV infections newly diagnosed (cases / million) 2014   0.1 0.0 50.9      
HIV prevalence (%) 2014   0.2% 0% 31%      
HCV prevalence (%) 2014   42.8% 15% 84%      
Drug-related deaths (rate/million) 2014   9.2 2.4 113.2      
Health and social responses                
Syringes distributed :   : 382 7 199 660      
Clients in substitution treatment 2012   28 656 178 161 388      
Treatment demand                
All clients 2014   10 630 271 100 456      
New clients 2014   5 600 28 35 007      
All clients with known primary drug 2014   10 630 271 97 068      
New clients with known primary drug 2014   5 600 28 34 088      
Drug law offences                
Number of reports of offences 2014   77 664 537 282 177      
Offences for use/possession 2014   60 447 13 398 422      

Key national figures and statistics

Content for Key national figures and statistics: 

p Eurostat provisional value.

b Break in series.

e Estimated.

: Not available.

1 Gross domestic product (GDP) is a measure of economic activity. It is defined as the value of all goods and services produced less the value of any goods or services used in their creation. The volume index of GDP per capita in Purchasing Power Standards (PPS) is expressed in relation to the European Union (EU-27) average set to equal 100. If the index of a country is higher than 100, this country's level of GDP per head is higher than the EU average and vice versa.

2  Expenditure on social protection contains: benefits, which consist of transfers in cash or in kind to households and individuals to relieve them of the burden of a defined set of risks or needs.

3 Unemployment rates represent unemployed persons as a percentage of the labour force. Unemployed persons comprise persons aged 15 to 74 who were: (a) without work during the reference week; (b) currently available for work; (c) actively seeking work.

4 Situation of penal institutions on 1 September, 2014.

5 Share of persons aged 0+ with an equivalent disposable income below the at-risk-of-poverty threshold, which is set at 60 % of the national median equivalised disposable income (after social transfers).

  Year   EU (27 countries) Source
Population  2014 76 667 864 506 944 075 bep Eurostat
Population by age classes 15–24  2014 16.6 % 11.3 % bep Eurostat
25–49 37.4 % 34.7 % bep
50–64 13.8 % 19.9 % bep
GDP per capita in PPS (Purchasing Power Standards) 1  2014 53 100 Eurostat
Total expenditure on social protection (% of GDP) 2  2013 14.1 % p : Eurostat
Unemployment rate 3  2015 10.3 % 9.4 % Eurostat
Unemployment rate of population aged under 25 years  2015 18.6 % 20.3 % Eurostat
Prison population rate (per 100 000 of national population) 4  2014 197.5  : Council of Europe, SPACE I-2014.1
At risk of poverty rate 5  2014 : 17.2 %  SILC

Contact information for our focal point

Address and contact: 

Turkish Monitoring Centre for Drugs and Drug Addiction (Türkiye Uyuşturucu ve Uyuşturucu Bağımlılığı İzleme Merkezi)

EMCDDA Türkiye Ulusal Temas Noktası

Meşrutiyet Mah. Konur Sokak No:40

TR-06640 Çankaya/Ankara
Tel. +90 312 462 8050-55
Fax: +90 312 462 8059

Head of national focal point: Mr Bülent Özcan

E-mail addresses have been inserted in a way discouraging spam. Please replace [a] by @ before actually using any of the e-mail addresses